Time: 3:44

Company News

TGA approval for CSL Behring lung therapy

The TGA has approved CSL Behring’s ZEMAIRA for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). AATD is a hereditary condition that can severely affect a patient’s lung function. The condition is marked by a low level or absence of Alpha-1 Proteinase Inhibitor (A1-PI), a natural protein that inhibits neutrophil elastase, thereby protecting the lungs from inflammation. Severe … Continue reading TGA approval for CSL Behring lung therapy

Innate MS trial on schedule for April completion

Innate Immunotherapeutics (ASX:IIL) has confirmed the clinical phase of the Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS) will be completed by the end of April as scheduled. Innate is conducting an exploratory double blinded, 2:1 randomised, placebo controlled study into the safety and efficacy of the its drug candidate MIS416 … Continue reading Innate MS trial on schedule for April completion

PolyNovo reports first patient treated in US

PolyNovo (ASX:PNV) has announced the first US patient has been treated with its Biodegradable Temporising Matrix (BTM). This patient’s complex trauma injury left the forearm and dorsal (upper) aspect of the hand de-gloved, said the company. “This exposes the tendons, like in free flap surgery, risking loss of function in the hand. The BTM should ensure full function … Continue reading PolyNovo reports first patient treated in US

Orthocell reports initial results from CelGro trial

Regenerative medicine company Orthocell (ASX:OCC) has announced positive initial safety and tolerability results for its CelGro collagen-based medical device, in a clinical study examining its use to augment the repair of nerve damage. The first two patients treated in the trial had previously suffered traumatic peripheral nerve injury resulting in the inability to bend their … Continue reading Orthocell reports initial results from CelGro trial

New senior appointment for Botanix

Medical dermatology company Botanix Pharmaceuticals has announced the appointment of Dr Michael Thurn as Chief Operating Officer. Dr Thurn has experience in drug development, having recently led development of a topical treatment for acne being developed by venture capital backed company Mimetica. As CEO of Mimetica, Dr Thurn guided a melancortin-5 receptor targeting drug from pre-clinical testing … Continue reading New senior appointment for Botanix

CSL delivers ‘exceptionally strong performance’

A very strong first half for CSL with the company reporting an 18 per cent jump in revenue to $3.677 billion and a 12 per cent jump in net profit to $806 million. “CSL’s exceptionally strong performance is a result of the focused execution of our strategy,” said CEO Paul Perreault. “Investments in commercial expansion and skills, … Continue reading CSL delivers ‘exceptionally strong performance’

MGC announces new medical cannabis study

MGC Pharmaceuticals, which is building a medical cannabis business, is commencing a six-week medical cannabis clinical study following the signing of an agreement with the University Children’s Hospital Ljubljana in Slovenia. The Phase IIA Crossover (non-pivotal) clinical study will use enriched medical cannabis products in children and adolescents with treatment-resistant epilepsy at the Hospital’s Department … Continue reading MGC announces new medical cannabis study

Pfizer to close Adelaide biologic facility

Pfizer has announced plans to close the largest biologic manufacturing site in Australia. The site in Adelaide, which currently employs 89 people and completed the final phase of a $21 million investment last year, will close by 2021. Pfizer acquired the site as part of its 2015 acquisition of Hospira. The facility manufactures biosimilar filgrastim for the global … Continue reading Pfizer to close Adelaide biologic facility